2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 343-345
Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, B Cell Lymphoma, Research, AML, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult
PAPER

561 Donor-derived multi-antigen-targeted T-cell therapy (CK-001) demonstrates graft-versus-leukemia activity with limited additional alloreactivity in relapsed acute myeloid leukemia following allogeneic hematopoietic cell transplantation

Monzr M. M Al Malki, MD, Sumithira Vasu, MBBS., MD2, Mathias Oelke, PhD3, Sojung Kim, PhD4, Kristi Jones5, Stephanie Bagully, PhD6, Wael Harb, MD MBA7, Juan Carlos Varela, MD PhD8
1 City of Hope, Duarte, California, United States
2 The Ohio State University, Columbus, Ohio, United States
3 CellKure, Frederick, Maryland, United States
4 CellKure, Frederick, Maryland, United States
5 CellKure, Frederick, Maryland, United States
6 CellKure, Frederick, Maryland, United States
7 CellKure, Frederick, Maryland, United States
8 Novant Health Cancer Institute, Winston Salem, North Carolina, United States
Patients with AML who relapse following allogeneic hematopoietic cell transplantation (HCT) have a dismal prognosis with a median survival of 4-6 months. Although donor lymphocyte infusion can restore graft-versus-leukemia (GVL) activity, its efficacy is limited and frequently accompanied by graft-versus-host disease (GVHD). CK-001 is a donor-derived, multi-antigen-targeting CD8+ T-cell product manufactured from leukapheresis obtained from the original allogeneic HCT donor using a novel Artificial Immune Modulating (AIM) nanoparticle platform. CK-001 targets five HLA-A*02:01-restricted peptide epitopes derived from WT1, PRAME, and Cyclin A1, antigens commonly overexpressed in AML. We report updated results from the phase 1 clinical trial of CK-001-001 (formerly CP-NEXI-001-01; NCT04284228).

HLA-A*02:01-positive patients with relapsed AML following allogeneic HCT and whose original HCT donors met eligibility criteria were enrolled. Original HCT donors underwent leukapheresis for manufacture of CK-001 using the AIM nanoparticle platform. Patients received lymphodepleting chemotherapy followed by CK-001 infusion. Primary objectives were safety and tolerability. Secondary objectives included clinical activity and correlative immune analyses.

Fourteen patients received CK-001. No dose-limiting toxicities occurred. Cytokine release syndrome (CRS) was limited to five grade 1–2 events in three patients (21%). Seven GVHD events were reported across the 14 dosed patients, including six in patients with prior GVHD and one case of mild de novo acute cutaneous GVHD. Three grade 4 serious adverse events occurred (neutropenia, aspiration, and pulmonary edema), and one patient died from progressive disease complicated by renal failure.

Among 14 dosed patients, 11 were evaluable for safety and efficacy, while 3 were evaluable for safety only (2 did not complete the DLT period and 1 received treatment under compassionate use). The efficacy-evaluable cohort represented a very high-risk population, with 10 (91%) harboring ≥3 adverse-risk molecular features and 8 of 10 patients with available ELN classification demonstrating adverse-risk AML. Median time from HCT to relapse was 9 months (range, 3–78). CK-001 was successfully manufactured from the original HCT donor in all evaluable patients, including 8 matched unrelated and 3 matched related donors.

Four patients achieved CR/CRi (1 CR and 3 CRi), including 2 MRD-negative remissions. Both patients with extensive baseline extra medullary disease (EMD) demonstrated objective reductions in EMD burden following CK-001, including complete resolution of EMD-related symptoms in one patient. Median overall survival was 201 days (range, 1.2–25.5 months), and 2 patients remained alive at data cutoff.

Correlative immune analyses demonstrated robust in vivo expansion of CK-001 antigen-specific T cells by day 29 following infusion, with a mean of 11.2% (range, 3.6–34.9%) of CD8+ T cells and 4.3% (range, 0.9–14.2%) of CD3+ T cells recognizing CK-001 target peptides across representative evaluable patients. Functional studies confirmed preserved proliferative capacity and effector function following expansion. Manufactured CK-001 products demonstrated a favorable immune memory phenotype enriched for stem cell memory (TSCM), central memory (TCM), and effector memory (TEM) subsets, consistent with the potential for long-term persistence and sustained antitumor activity. Despite infusion of an exclusively CD8+ T-cell product, peripheral CD4+ T-cell populations rapidly recovered without an associated increase in chronic GVHD, supporting immune reconstitution without evidence of broad enhancement of alloreactivity.

CK-001 demonstrated a favorable safety profile and encouraging clinical activity in patients with AML relapsing after allogeneic HCT. Responses occurred despite uniformly adverse-risk disease in a population with historically poor outcomes following post-transplant relapse. The observed clinical benefit (including complete remissions), reductions in extramedullary disease, limited de novo GVHD, and immune correlates demonstrating antigen-specific T-cell expansion supports further evaluation of donor-derived, multiantigen-targeting T-cell therapy to augment graft-versus-leukemia activity while minimizing alloreactivity following allogeneic HCT.
Monzr M. M Al Malki, MD: incyte - Research Funding; gamida cell - Consultancy (Includes expert testimony); Ossium Health - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Jazz Pharma - Consultancy (Includes expert testimony); Tr1x - Consultancy (Includes expert testimony); Tscan Therapeutics - Consultancy (Includes expert testimony)